Cross-cultural Adaptation and Validation of the Brazilian Version of the Scleroderma Health Assessment Questionnaire (SHAQ)

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2013 Aug 27

PMID 23975361

Citations 3

Authors

Luiza F Rocha

Roberta G Marangoni

Percival D Sampaio-Barros

Mauricio Levy-Neto

Natalino H Yoshinari

Eloisa Bonfa

Virginia Steen

Sergio C Kowalski

Affiliations

Soon will be listed here.

Abstract

The Scleroderma Health Assessment Questionnaire (SHAQ) is a feasible multisystem specific tool that has been extensively used as an additional assessment for systemic sclerosis (SSc). The aim of this study is to cross-culturally adapt and validate the Brazilian version of the SHAQ. Construct validity was assessed based on the correlations between SHAQ and both the Medical Outcomes Survey Short Form 36 version 2 (SF-36v2™) and the Health Assessment Questionnaire Disability Index (HAQ-DI). The correlation between the SHAQ and disease severity was assessed by Spearman's correlation coefficient. The reproducibility of the SHAQ was evaluated by the intraclass correlation coefficient (ICC). Among the 151 consecutive outpatients evaluated, 59 % had limited SSc subtype. The overall disease severity visual analog scale (VAS) of the SHAQ was statistically significantly correlated to HAQ-DI, pain VAS, and the SF-36v2™ physical component summary score (r = 0.595, r = 0.612, and r = -0.582, respectively; p < 0.001). Further analysis of all SF-36v2™ components revealed statistically significant correlations between overall disease severity VAS and bodily pain (r = -0.621, p < 0.001), vitality (r = -0.544, p < 0.001), physical function (r = -0.510, p < 0.001), and role limitation-physical dimensions (r = -0.505, p < 0.001). Moreover, digestive, pulmonary, and overall disease severity VASs were statistically significantly correlated to the number of organs involved (r = 0.178, p = 0.029; r = 0.214, p = 0.008; r = 0.282, p < 0.001). We also demonstrated high reproducibility for SHAQ (ICC = 0.757, 95 % confidence interval = 0.636-0.842). The Brazilian version of the SHAQ demonstrated both construct and discriminant validities as well as good reproducibility.

Citing Articles

Validation of the Portuguese Version of the Scleroderma Health Assessment Questionnaire.

Genrinho I, Ferreira P, Santiago T, Carones A, Mazeda C, Barcelos A Int J Environ Res Public Health. 2023; 20(22).

PMID: 37998293 PMC: 10671070. DOI: 10.3390/ijerph20227062.

Translation and validation of the Persian version of the scleroderma health assessment questionnaire (SHAQ).

Nayebirad S, Emamzade A, Sedaghat M, Montazeri A, Gharibdoost F, Yaseri M Intern Emerg Med. 2023; 18(3):811-819.

PMID: 36854998 DOI: 10.1007/s11739-023-03229-4.

Validation of Turkish version of the Scleroderma Health Assessment Questionnaire.

Temiz Karadag D, Karakas F, Tekeoglu S, Yazici A, Ozdemir Isik O, Cefle A Clin Rheumatol. 2019; 38(7):1917-1923.

PMID: 30840212 DOI: 10.1007/s10067-019-04494-5.

References

Rannou F, Poiraudeau S, Berezne A, Baubet T, Le-Guern V, Cabane J . Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum. 2007; 57(1):94-102. DOI: 10.1002/art.22468. View

Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

Khanna D, Furst D, Clements P, Park G, Hays R, Yoon J . Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol. 2005; 32(5):832-40. View

Georges C, Chassany O, Mouthon L, Tiev K, Toledano C, Meyer O . Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol. 2005; 24(1):3-10. DOI: 10.1007/s10067-004-0942-3. View

Fries J, Spitz P, Young D . The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982; 9(5):789-93. View

Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A . Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005; 8(2):94-104. DOI: 10.1111/j.1524-4733.2005.04054.x. View

Ruof J, Bruhlmann P, Michel B, Stucki G . Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology (Oxford). 1999; 38(6):535-42. DOI: 10.1093/rheumatology/38.6.535. View

Charles C, Clements P, Furst D . Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006; 367(9523):1683-91. DOI: 10.1016/S0140-6736(06)68737-0. View

Smyth A, MacGregor A, Mukerjee D, Brough G, Black C, Denton C . A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology (Oxford). 2003; 42(6):732-8. DOI: 10.1093/rheumatology/keg145. View

10.

Montagna G, Cuomo G, Chiarolanza I, Ruocco L, Valentini G . [HAQ-DI Italian version in systemic sclerosis]. Reumatismo. 2006; 58(2):112-5. DOI: 10.4081/reumatismo.2006.112. View

11.

Laguardia J, Campos M, Travassos C, Najar A, Anjos L, Vasconcellos M . Psychometric evaluation of the SF-36 (v.2) questionnaire in a probability sample of Brazilian households: results of the survey Pesquisa Dimensões Sociais das Desigualdades (PDSD), Brazil, 2008. Health Qual Life Outcomes. 2011; 9:61. PMC: 3162522. DOI: 10.1186/1477-7525-9-61. View

12.

Ware Jr J, Kosinski M, Bayliss M, McHorney C, Rogers W, Raczek A . Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995; 33(4 Suppl):AS264-79. View

13.

Hudson M, Steele R, Lu Y, Thombs B, Panopalis P, Baron M . Clinical correlates of self-reported physical health status in systemic sclerosis. J Rheumatol. 2009; 36(6):1226-9. DOI: 10.3899/jrheum.081057. View

14.

Hudson M, Thombs B, Steele R, Panopalis P, Newton E, Baron M . Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum. 2009; 61(8):1112-20. DOI: 10.1002/art.24676. View

15.

Ostojic P, Damjanov N . The scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol. 2006; 65(2):168-75. DOI: 10.1007/s00393-005-0006-3. View

16.

Khanna D, Yan X, Tashkin D, Furst D, Elashoff R, Roth M . Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007; 56(5):1676-84. DOI: 10.1002/art.22580. View

17.

Pope J . Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S98-111. DOI: 10.1002/acr.20598. View

18.

Khanna D, Hays R, Park G, Braun-Moscovici Y, Mayes M, McNearney T . Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum. 2007; 57(7):1280-6. DOI: 10.1002/art.22987. View

19.

Steen V, Medsger Jr T . The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997; 40(11):1984-91. DOI: 10.1002/art.1780401110. View

20.

Clements P, Wong W, Hurwitz E, Furst D, Mayes M, White B . The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum. 2001; 44(3):653-61. DOI: 10.1002/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q. View